For instance, anti–programmed death-1 (anti-PD1) monoclonal antibody, pembrolizumab, combined with chemotherapy, has been proven effective in Non-small cell lung cancer (NSCLC) patients whereas treatment with another (anti-PD1) monoclonal antibody, nivolumab, combined with the monoclonal antibody ipilimumab, which enhances the T-cell response by targeting cytotoxic T lymphocyte–associated antigen 4 (CTLA-4), has been fruitful to treat cancer in advanced melanoma patients (11, 12). Here, CTLA4 is linked to non-small cell lung carcinoma.